On this page
The description: support you cannot add laterThe abstract: short, public and hard to fixSequence listings: translate the free text, nothing elseFormulas and chemical namesA pre-filing check for the parts outside the claimsOn most patent translation jobs the claims get two reviews and a call with the attorney. The description gets one careful pass. The abstract, the sequence listing and the formula pages get whatever time is left on the last afternoon before filing. That ordering makes sense for scope, but it is also why so many avoidable errors in Korean filings sit outside the claims, in parts that nobody reads closely until an examiner, a searcher or an opponent does.
This post walks through those parts one at a time: what each is for, the mistake that typically appears there, and what to check. Claim language is covered elsewhere, in why claim translation is the most critical part of a patent.
The description: support you cannot add later
The description is where claim terms get their meaning and where later amendments must find their basis. For a foreign-language application in Korea, the Korean Patent Act lets the applicant correct errors in the final Korean translation, but only during the period in which amendments are allowed (Article 42-3(6) for direct filings, Article 201(6) for PCT national phase entries). And for PCT applications, the scope of what can be amended is measured against the description, claims and drawings as filed on the international filing date (Article 208(3)). In practice: a correction can bring the Korean text back in line with the original, but it cannot add what the original never said.
Three description errors come up again and again:
| Error | Why it happens | Why it hurts |
|---|---|---|
| A claim term translated two ways | Different translators, or the claims done after the description without a termbase | The claim term no longer has visible support; the examiner may ask which meaning applies |
| Optional language turned definite | "May include", "in some embodiments" flattened into plain statements | An example reads like a requirement and can later be used to read the claims narrowly |
| Reference numerals out of sync | Numbers retyped instead of copied, or sentences reordered without moving the numeral | Text and figures disagree; see the risks of incorrect figure reference translation |
The abstract: short, public and hard to fix
Everyone knows the abstract does not define scope. Korean Patent Act Article 43 says so directly. That is exactly why it gets rushed. But the abstract has its own rules and its own audience.
Under PCT Rule 8.1, the abstract summarises the disclosure, names the technical field, must not state the alleged merits of the invention, and should preferably be 50 to 150 words "if it is in English or when translated into English". Main technical features shown in a drawing are followed by their reference sign in parentheses. Rule 8.3 says the abstract should work as a scanning tool for searchers.
WIPO's practical advice adds two points translators rarely hear. First, the International Searching Authority decides the final content of the abstract and may rewrite it, which causes rework and republication. Second, errors in the abstract cannot be corrected through a request to rectify obvious mistakes. A sloppy abstract stays sloppy in the published record.
English abstract sentence
A valve assembly (10) includes a housing (12), a spool (14) slidable in the housing, and a spring (16) biasing the spool toward a closed position, providing quieter operation.Reference signs in place, one effect phrase at the end.What often comes back
The draft opens with a stock "the present invention relates to" phrase, lists housing, spool and spring with no reference signs, leaves out what the spring does, and calls the assembly "innovative" with "excellent" quietness.Reference signs dropped, the spring's function lost, and praise added that the rule asks you to leave out.Length is a second trap, mainly for Korean applicants going abroad. Word counts do not carry over between Korean and English, and the rule measures length in English. A Korean abstract that looks compact can come out well past 150 words once it is translated into English for international publication. If the Korean abstract is written to the limit, plan for a trimmed English version rather than hoping the count works out.
Sequence listings: translate the free text, nothing else
Biotech filings carry a sequence listing in XML under WIPO Standard ST.26. Most of that file must not be translated at all. The PCT Administrative Instructions (Annex C) are precise on this:
- Only the language-dependent free text is translated: descriptive notes such as "synthetic primer" or a short description of a modified residue.
- The sequences themselves, numeric and date values, and the controlled vocabulary are left untouched.
- A translation is delivered as a new sequence listing, with the free text in the required language and the rest of the file unchanged apart from items such as the production date and language code.
- ST.26 allows free text in English, in another language, or both, in separate elements for each.
- In the national phase, an Office may require a translated listing under PCT Rule 49.5, but not merely because the existing listing contains a second language.
Keep the numbering, too. Annex C asks for the original sequence identifiers to be kept where possible, because the description and claims refer to them by number. A listing that renumbers while the description does not is the biotech version of a broken figure reference.
Formulas and chemical names
PCT Rule 11.10 allows chemical and mathematical formulae in the description, the claims and the abstract. Formulas look language-neutral, so they are often pasted in and skipped. They are not neutral once the surrounding text is translated.
- Variable definitions. "Wherein R1 is hydrogen or C1-C6 alkyl, and R2 is as defined above" refers back to a definition that may have moved in the reordered Korean sentence. Check that every variable is defined once, before use, and that "as defined above" still points to the right place.
- Markush groups. "Selected from the group consisting of" is a closed list. A Korean rendering that reads like "such as" opens it. The same logic is covered in how a translation can weaken a patent without breaking it.
- Numbers inside formulas. Subscripts, primes, decimal points and ranges are retyped more often than you would think. One character can change a compound or a range; how a single number can change the meaning of a patent shows how far that goes.
- Chemical names. IUPAC's 2013 recommendations define a single preferred IUPAC name for each structure, but state that other unambiguous names remain acceptable. The translation does not need to "upgrade" a trade or trivial name to a systematic one. It needs to name the same compound, with every locant and prime intact, and use the same name throughout. Where a name and a drawn structure appear together, check one against the other.
A pre-filing check for the parts outside the claims
- Run a term-consistency report: every claim term should appear in the description in the same Korean form.
- Compare reference numerals in text and figures automatically, not by eye.
- Read the abstract against Rule 8: field named, no merit language, reference signs present, length checked in English.
- Translate the sequence listing in a locked file where only free-text values are editable; validate the result.
- Check every formula variable is defined, every Markush group stays closed, and every chemical name matches its structure.
- Leave time for this. Running out of days before the national phase deadline is how these parts get skipped; see PCT translation risks before the 30-month deadline.
Filing a biotech or chemistry case in Korea, or sending one abroad? We translate the whole specification, sequence listings included, and check the parts that usually get skipped. See our services or send us the file list.